Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy

Journal of Drug Targeting

Volumn 19, Issue 5, 2011, Pages 336-343

  Lee, Yonghyun ^a   Kim, In Ho ^a   Kim, Jeongyun ^a   Yoon, Jeong Hyun ^a   Shin, Young Hee ^b   Jung, Yunjin ^a   Kim, Young Mi ^a  

^a Pusan National University   (South Korea)

^b Kyungsung University   (South Korea)

Author keywords

colon specific delivery; dextran; Dextran flufenamic acid ester; flufenamic acid; sustained release; ulcerogenicity

Indexed keywords

ANTIINFLAMMATORY AGENT; BUFFER; DEXTRAN; DEXTRAN FLUFENAMIC ACID ESTER; DEXTRANASE; FLUFENAMIC ACID; IMIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; POLYMER DIRECTED ENZYME PRODRUG THERAPY; PRIORITY JOURNAL; RAT; STOMACH ULCER; SUSTAINED DRUG RELEASE; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CECUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; DELAYED-ACTION PREPARATIONS; DEXTRANS; DRUG CHRONOTHERAPY; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLUFENAMIC ACID; GASTRIC MUCOSA; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; MALE; MOLECULAR STRUCTURE; PEPTIC ULCER; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION;

EID: 79955575774     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.499462     Document Type: Article

References (18)

1. Andrew DM. (1992) Dextran prodrugs for colonic-specific drug delivery. In: Friend, D. R. (ed.) Oral colon specific drug delivery. CRC Press, Boca Raton, Fl, pp. 213-231.
2. Bruguerolle B, Labrecque G. (2007). Rhythmic pattern in pain and their chronotherapy. Adv Drug Deliv Rev, 59, 883-895. (Pubitemid 47531899)
3. Harboe E, Larsen C, Johansen M, Olesen HP. (1989). Macromolecular prodrugs. XV. Colon-targeted delivery-bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. Pharm Res, 6, 919-923. (Pubitemid 20078440)
4. Jung YJ, Lee JS, Kim HH, Kim YT, Kim YM. (1998). Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res, 21, 179-186. (Pubitemid 128660994)
5. Kalala W, Kinget R, van den Mooter G, Samyn C. (1996). Colonic drug-targeting:in vitro release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. Int J Pharmaceutics, 139, 187-195. (Pubitemid 26276281)
6. Kim H, Kong H, Choi B, Yang Y, Kim Y, Lim MJ, Neckers L, Jung Y. (2005). Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res, 22, 1499-1509. (Pubitemid 41215890)
7. Kinget R, Kalala W, Vervoort L, van den Mooter G. (1998). Colonic drug targeting. J Drug Target, 6, 129-149. (Pubitemid 29033981)
8. Larsen C, Harboe E, Johansen M, Olesen HP. (1989). Macromolecular prodrugs. XVI. Colon-targeted delivery-comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res, 6, 995-999. (Pubitemid 20094220)
9. Larsen C, Jensen BH, Olesen HP. (1991). Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord, 3, 71-76.
10. Lee JS, Jung YJ, Doh MJ, Kim YM. (2001). Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm, 27, 331-336.
11. McLeod AD, Friend DR, Tozer TN. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int J Pharm, 92, 105-114. (Pubitemid 23159842)
12. McLeod AD, Friend DR, Tozer TN. (1994). Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci, 83, 1284-1288. (Pubitemid 24282335)
13. Nambu N, Kikuchi K, Kikuchi T, Takahashi Y, Ueda H, Nagai T. (1978). Influence of inclusion of nonsteroidal antiinflammatory drugs with beta-cyclodextrin on the irritation to stomach of rats upon oral administration. Chem Pharm Bull, 26, 3609-3612. (Pubitemid 9109324)
14. Nielsen LS, Weibel H, Johansen M, Larsen C. (1992). Macromolecular prodrugs. XX. Factors influencing model dextranase-mediated depolymerization of dextran derivatives in vitro. Acta Pharm Nord, 4, 23-30.
15. Sery TW, Hehre EJ. (1956). Degradation of dextrans by enzymes of intestinal bacteria. J Bacteriol, 71, 373-380.
16. Shen TY. (1983) Nonsteroidal anti-inflammatory agents. In: Wolff, M. E. (ed.) Burger's Medicinal Chemistry. 4th edn. John Wiely & Sons, New York, pp. 1229-1233.
17. Sinha VR, Kumria R. (2001). Polysaccharides in colon-specific drug delivery. Int J Pharm, 224, 19-38. (Pubitemid 32706482)
18. Smolensky MH, Peppas NA. (2007). Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev, 59, 828-851. (Pubitemid 47542291)